Jaguar Gene Therapy focuses on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, according to their self-described mission.

Jaguar Gene Therapy

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Peter Diamandis

Andrew L. Pecora

Robert J. Hariri

Celularity Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Steve Harr

Jack Milwid

Michael Mee

Jacob Rubens

Sonja Schrepfer

Geoffrey von Maltzahn

Sana Biotechnology, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Jaguar Gene Therapy	Celularity Inc.	Sana Biotechnology, Inc.	Alnylam Pharmaceuticals, Inc.
Symbol		CELU	SANA	ALNY
MSH ID	COM:JAGUARGENETHERAPY	COM:CELULARITY	COM:SANA	COM:ALNYLAM
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage	Venture Round
Employee Count		225	328	2.10K
Website	jaguargenetherapy.com	celularity.com	sana.com	alnylam.com
LinkedIn		celularity	sana-biotechnology
Founders

Metric
Market Cap		61.43M	1.15B	32.60B
Enterprise Value
Monthly Web Traffic	1		22.72K	55.97K
Web Traffic Growth	-1.00		1.04	0.89
Valuation
Raised Capital			165M	900M

Metric
Revenue	22.77M	1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.75M	1.52B
EBITDA	-74.30M	-228.12M
Operating Income	-192.29M	-282.18M
Net Income	-196.29M	-440.24M
EPS	-11.02	-3.52
Diluted EPS	-11.02	-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.57	0.87
Operating Profit Margin	-4.05	0.04
EBITDA Margin	-3.26	-0.12
Net Profit Margin	-4.60	-0.03
Return on Equity	-1.44	1.67
Return on Assets	-0.92	-0.02
Return on Capital Employed	-1.68	0.03

COM:JAGUARGENETHERAPY

Jaguar Gene Therapy

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.49	-42.10
P/B Ratio	2.93	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	7.73	16.84
EV Multiple	0.56	326.32

Metric
Days Sales Outstanding	152.68	68.92
Days Payables Outstanding	132.68	97.72
Days Inventory Outstanding	147.30	128.53
Operating Cycle	382.12	187.09
Cash Conversion Cycle	117.55	104.98
Asset Turnover	0.23	0.58

Metric
Operating Cash Flow	-38.69M	104.16M
Free Cash Flow	-42.73M	41.95M
Cash Flow to Debt	-0.36	0.15
Operating Cash Flow/Sales	-0.84	0.16
Free Cash Flow Yield	-0.67	-0.00

Metric
Cash & Equivalents	227K	812.69M
Accounts Receivable	-6.83M	-87.94M
Inventory	5.75M	89.15M
Goodwill	7.35M
Debt to Capitalization	0.68	1.20
Debt to Assets	0.39	0.34
Current Ratio	0.19	3.14
Quick Ratio	0.29	3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.07	0.13
R&D to Revenue	2.82	0.58
SG&A to Revenue		0.35